Pure glucagon antagonists: Biological activities and camp accumulation using phosphodiesterase inhibitors

Peptides

Volumn 18, Issue 5, 1997, Pages 633-641

  Azizeh, Bassem Y ^a,b   Van Tine, Brian A ^a   Trivedi, Dev ^a   Hruby, VictorJ ^a,c  

^a University of Arizona ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Adenylate cyclase; Amrinone; cAMP accumulation; Glucagon antagonists; Hepatocytes; IBMX; Phosphodiesterase inhibitors; Receptor binding; Rolipram; Structure activity relationships

Indexed keywords

AMRINONE; CYCLIC AMP; GLUCAGON; GLUCAGON DERIVATIVE; ISOBUTYLMETHYLXANTHINE; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM;

ANIMAL TISSUE; ARTICLE; DIABETES MELLITUS; DRUG SYNTHESIS; GLUCAGON RELEASE; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ADENYLATE CYCLASE; ANIMALS; CATTLE; CYCLIC AMP; GLUCAGON; HUMANS; LIVER; MALE; PHOSPHODIESTERASE INHIBITORS; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; SENSITIVITY AND SPECIFICITY;

ANIMALIA;

EID: 0030794042     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(97)00131-9     Document Type: Article

References (44)

1. Azizeh B. Y., Shenderovich M. D., Trivedi D., Li G., Sturm N. S., Hruby V. J. Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences. J. Med. Chem. 39:1996;2449-2455.
2. 9]glucagon amide: A newly designed "pure" glucagon antagonist. Bioorg. Med. Chem. Lett. 5:1995;1849-1852.
3. Beavo J. A. Multiple isozymes of cyclic nucleotide phosphodiesterase. Adv. Second Messenger & Phosphoprotein Res. 22:1988;1-38.
4. Beavo J. A., Conti M., Heaslip R. J. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharm. 46:1994;399-405.
5. Berry M. N., Friend D. S. High-yield preparation of isolated liver parenchymal cells: A biochemical and fine structural study. J. Biol. Chem. 43:1969;506-520.
6. Braun W., Wider G., Lee K. H., Wüthrich K. Conformation of glucagon in a lipid-water interface by 1H nuclear magnetic resonance. J. Mol. Biol. 169:1983;921-948.
7. Brown B. L., Ekins R. P., Albano J. M. P. Saturation assay for cAMP using endogenous binding protein. Adv. Cyclic Nucleotide Res. 2:1972;25-40.
8. Dharanipragada R., Trivedi D., Bannister A., Siegel M., Tourwe D., Mollova N., Schram K., Hruby V. J. Synthetic linear and cyclic glucagon antagonists. Int. J. Peptide Protein Res. 42:1993;68-77.
9. Fields G. B., Nobl R. L. Soli phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Peptide Protein Res. 35:1990;161-214.
10. Gysin B., Johnson D. G., Trivedi D., Hruby V. J. Synthesis of two glucagon antagonists: Receptor binding, adenylate cyclase, and effects on blood glucose levels. J. Med. Chem. 30:1987;1409-1415.
11. Gysin B., Trivedi D., Johnson D. G., Hruby V. J. Design and synthesis of glucagon partial agonists and antagonists. Biochemistry. 25:1986;8278-8284.
12. 125I]monoiodoglucagon by isolated canine hepatocytes. J. Biol. Chem. 259:1983;8986-8993.
13. Heyworth C. M., Houslay M. D. Challenge by hepatocytes by glucagon triggers a rapid modulation of adenylate cyclase activity in isolated membranes. Biochem J. 214:1983;93-98.
14. Heyworth C. M., Wallace A. V., Wilson S. R., Houslay M. D. An assessment of the ability of insulin-stimulated cAMP phosphodiesterase to decrease hepatocyte intracellular cAMP concentrations. Biochem. J. 222:1984;183-187.
15. Houslay M. D. The use of selective inhibitors and computer modeling to evaluate the role of specific high affinity cyclic AMP phosphodiesterases in the hormonal regulation of hepatocyte intracellular cyclic AMP concentrations. Cell. Signal. 2:1990;85-98.
16. Hruby V. J. Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs. Mol. Cell. Biochem. 44:1982;49-64.
17. Johnson D. G., Goebel C. U., Hruby V. J., Bregman M. D., Trivedi D. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science. 215:1982;1115-1116.
18. 125I]glucagon by anion exchange chromatography. Horm. Metab. Res. 4:1972;223-224.
19. Korn A. P., Ottensmeyer F. P. A model for the three-dimensional structure of glucagon. J. Theor. Biol. 105:1983;403-425.
20. Krystenansky J. L., Trivedi D., Hruby V. J. Importance of the 10-13 region of glucagon for its receptor interactions and activation of adenylate cyclase. Biochemistry. 25:1986;3833-3839.
21. Lavan B. E., Lakey T., Houslay M. D. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form. Biochem. Pharmacol. 38:1989;4123-4136.
22. 29)(homoserine lactone-27)glucagon. Biochemistry. 14:1975;1559-1563.
23. 2+ pump which is mediated by G proteins. J. Biol. Chem. 165:1990;9876-9880.
24. Lundt B. F., Johansen N. L., Volund A., Markussen J. Removal of t-butyl and t-butoxycarbonyl protecting groups with trifluoroacetic acid. Mechanism, biproduct formation and evaluation of scavengers. Int. J. Peptide Protein Res. 12:1978;258-268.
25. 1, N epsilon-acetimidoglucagon: Structure-function relationship. Arch. Biochem. Biophys. 257:1987;379-386.
26. Markwell M. A. K., Haas S. M., Bieleer L. L., Tolbert N. E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87:1978;206-210.
27. McLaughlin M. M., Cieslinski L. B., Burman M., Torphy T. J., Livi G. P. A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein and tissue distribution of mRNA. J. Biol. Chem. 268:1993;6470-6476.
28. Merrifiel R. B. Solid phase peptide synthesis: The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85:1963;2149-2154.
29. Neville D. M. Jr. Isolation of an organ specific protein antigen from cell surface membrane of rat liver. Biochim. Biophys. Acta. 154:1968;540-552.
30. Pavoine C., Brechler V., Kervan A., Blache P., Le-Nguyen D., Laurent S., Bataille D., Pecker F. Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon. Am. Phys. Soc. 260:1991;C993-C999.
31. Pohl S. L., Birnbaumer L., Rodbell M. The glucagon-sensitive adenylate cyclase system in membranes of rat liver. Comparison between glucagon- and fluoride- stimulated activities. J. Biol. Chem. 246:1971;1849-1856.
32. Salomon Y., Londos G., Rodbell M. A highly sensitivity adenylate cyclase assay. Anal. Biochem. 58:1976;541-548.
33. Sasaki K., Dockerill S., Adamiak D. A., Tickle I. J., Blundell T. X-ra analysis of glucagon and its relationship to receptor binding. Nature. 257:1975;751-757.
34. Schild H. O. A new scale for the measurement of drug antagonism. Br. J. Pharmacol. 2:1947;189-206.
35. Unger R. H. Diabetes and the alpha cell. Diabetes. 25:1976;136-151.
36. Unger R. H., Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet. 1:1975;14-16.
37. Unson C. G., Andreu D., Gurzenda E. M., Merrifield R. B. Synthetic peptide antagonists of glucagon. Proc. Natl. Acad. Sci. USA. 84:1987;4083-4087.
38. Unson C. G., Cheung C. P., Wu C.-R., Merrifield R. B. Interaction of the glucagon receptor and a D64K mutant with position 12, 17, and 18 replacement analogs of glucagon, Peptides Chemistry, Structure and Biology. Kaumaya P. T. P., Hodges R. S. Proceedings of the 14th American Peptide Symposium. 1996;360-361 ESCOM Sci. Publ, Leiden.
39. 9]glucagon amide, a glucagon antagonist. Peptides. 10:1989;1171-1177.
40. Unson C. G., MacDonald D., Merrifield R. B. The role of histidine-1 in glucagon action. Arch. Biochem. Biophys. 300:1993;747-750.
41. Unson C. G., Macdonald D., Ray K., Durrah T. L., Merrifield R. B. Position 9 replacement analogs of glucagon uncouple biological activity and receptor binding. J. Biol. Chem. 266:1991;2763-2766.
42. 2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinology. 137:1996;3316-3322.
43. Wilson M., Sullivan M., Brown N., Houslay M. D. Purification, characterization and analysis of rolipram inhibition of a human type-IVA cyclic AMP-specific phosphodiesterase expressed in yeast. Biochem. J. 304:1994;407-415.
44. Zechel C., Trivedi D., Hruby V. J. Synthetic glucagon antagonists and partial agonists. Int. J. Peptide Protein Res. 38:1991;131-138.